Penn Medicine Develops Novel mRNA Vaginal Gel Therapy for Heavy Menstrual Bleeding
Key Insights
Penn Medicine (search) researchers are developing an innovative mRNA-based vaginal gel (search) therapy to treat heavy menstrual bleeding (search), which affects one in three women and causes a woman to require blood transfusion every minute in the U.S.
The therapy uses lipid nanoparticles (search) to deliver mRNA directly to endometrial tissue, targeting proteins involved in vasoconstriction and tissue repair pathways to reduce abnormal bleeding.
Wellcome Leap (search)'s Missed Vital Sign program is providing up to $5 million in funding, aiming to reduce treatment waiting times from the current average of five years to just five months.
Penn Medicine (search) researchers are pioneering a groundbreaking mRNA-based therapy to address heavy menstrual bleeding (search), a condition affecting one in three women that has long been overlooked by the medical community. The innovative treatment, led by Dr. Kathleen O'Neill, assistant professor of obstetrics and gynecology and director of the uterine transplant program, represents the first application of mRNA technology to women's reproductive health.
Revolutionary Approach to an Underserved Condition
Heavy menstrual bleeding (search) presents a significant health burden, with every minute in the U.S. requiring a woman to receive a blood transfusion because of her period. The condition regularly interferes with everyday life, causing women to miss school or work and potentially leading to adverse health conditions like anemia (search). Despite affecting millions of women, "our resources for treating it are incredibly limited," Dr. O'Neill emphasized.
The research team is developing a vaginal gel (search) composed of lipid nanoparticles (search) that will deliver mRNA to the endometrial tissue to restore production of proteins critical in limiting menstrual bleeding. This approach extends the proven success of mRNA technology, famous for COVID-19 vaccines, into the field of women's health.
Targeting Key Biological Pathways
Previous research has identified specific biological pathways that may contribute to heavy periods. The therapy focuses on two critical processes: vasoconstriction, which causes blood vessels to narrow and reduce blood flow, and proliferation repair, involved in regenerating new tissue during wound healing and the monthly breakdown and renewal of the endometrium (search).
Data from past studies in both animals and humans has pinpointed genes and proteins involved in these pathways that appear to be present at lower or higher levels in women with heavy menstrual bleeding (search). The mRNA gel aims to regulate these proteins directly within the endometrial tissue.
Substantial Funding and Collaborative Effort
Wellcome Leap (search)'s Missed Vital Sign program is providing up to $5 million in funding for this research. The program represents a $50 million investment to better quantify heavy menstrual bleeding (search), understand its causes, develop new treatments, and raise awareness among the public and healthcare providers about normal versus abnormal menstrual bleeding.
Co-investigators include Dr. Jillian Melamed, a research assistant professor of infectious diseases at Penn who works in Drew Weissman's lab, Kara McKinley from Harvard University, and Kelsey Swingle from Rice University. Notably, Penn's Drew Weissman and Katalin Karikó pioneered the revolutionary mRNA technology used in COVID-19 vaccines.
Addressing Current Treatment Limitations
Current treatments for heavy menstrual bleeding (search) are severely limited. When bleeding relates to uterine fibroids (search), surgery to remove the fibroids can help reduce menstrual flow. Patients may also benefit from hormonal interventions like birth control pills (search) or intrauterine devices (IUDs), which thin the endometrial lining to reduce bleeding. However, surgery and hormones can have significant risks and side effects and are not appropriate for everyone.
The condition often indicates underlying health issues such as uterine fibroids (search), thyroid disease (search), bleeding disorders (search), and pituitary tumors (search), yet healthcare professionals frequently overlook this symptom. No clear measure or marker exists to define "normal" bleeding, and many women with heavy menstrual bleeding (search) don't realize their cycles aren't typical.
Preclinical Development and Future Vision
The team will initially test the treatment in samples of human endometrial tissue and specially engineered mouse models that have menstrual cycles mimicking those of human women. If successful in these preclinical studies, the researchers hope to eventually test the safety and efficacy of the mRNA vaginal gel (search) in clinical trials.
"The hope is that we can eventually develop a new therapy for heavy menstrual bleeding (search) that isn't hormonal, doesn't require surgery, and can be easily administered at home," Dr. O'Neill explained. Even if the initial protein targets don't succeed, having a medication that safely delivers mRNA to the uterus would serve as a valuable platform for testing future protein targets as scientists continue learning about the diverse causes of heavy menstrual bleeding.
Ambitious Timeline Goals
The Missed Vital Sign program aims to dramatically reduce the time it takes a woman to receive effective treatment for heavy menstrual bleeding (search), from the current average of five years to just five months. "It's a lofty goal, but we're trying to make an impact on a big problem—and one that has gotten insufficient attention," Dr. O'Neill stated. "Good science needs to be rigorous, but it sometimes moves too slowly. We have big ideas and want to move things along with a sense of urgency."